Jaffer Ajani

60PUBLICATIONS
283CO-AUTHORS
Predictive and prognostic markersDisease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (60)

|Nov 02, 2026
RhoA Y42C drives cell plasticity and PD-1-mediated immune evasion of diffuse gastric cancer.

|Sep 27, 2026
Automated detection of gastroesophageal adenocarcinoma recurrence from electronic health records.

|May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

|Apr 19, 2026
Clinical Machine Learning Model for Predicting Pathological Complete Response in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma After Trimodality Therapy.

|Mar 04, 2026
Association of Blood Levels of Forever Plastics with Lung Cancer Mortality among Ever Smokers in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cohort Study.

Ehsan Irajizad, Johannes F Fahrmann, Ranran Wu

|Dec 03, 2025
Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons.

Jaffer A Ajani, Kaijun Wang, Georgios F Nikolaidis

Pageof 10

Frequent Collaborators

12 joint publications

Shumei Song

7 joint publications

Linghua Wang

6 joint publications

Kohei Shitara

5 joint publications

Funda Meric-Bernstam